Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company ...

Traws Pharma is burning cash In November, Traws Pharma reported $8.5 million of net loss for its third quarter that translates to $8.81 per share. The number was up significantly from $4.7 million ...

About Traws Pharma, Inc. Antiviral ProgramTraws Pharma is a clinical stage biopharmaceutical company developing potential oral small molecule therapies for the treatment of respiratory viral diseases.

Tivoxavir marboxil (TXM), administered as a single dose in non-human primates, significantly reduced lung viremia and prevented weight loss, two key measures of antiviral activity in preclinical ...

NEWTOWN, Pa., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW) (“Traws” or “the Company”), a clinical-stage biopharmaceutical company ...

May 16, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral diseases ...

Traws Pharma earnings missed by $4.62, revenue fell short of estimates ...

In vivo study in mice, with H5N1 isolated from an infected dairy worker, showed potent protection and suppression of virus replication in lungs Phase 2 study expected to begin in H1 2025 Traws ...